Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
10:30am, Thursday, 21'st Nov 2024
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas, Inc.") (NASDAQ:ARVN) concerning possible violatio
NEW YORK CITY, NY / ACCESSWIRE / November 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:
Arvinas, Inc. (ARVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
12:15pm, Wednesday, 20'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas, Inc.") (NASDAQ:ARVN) concerning possible violatio
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
12:00pm, Wednesday, 20'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advise
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
03:45pm, Tuesday, 19'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space (SCS
Arvinas to Participate in Upcoming Investor Conferences
07:00am, Monday, 04'th Nov 2024
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript
03:43pm, Wednesday, 30'th Oct 2024
Arvinas, Inc. (NASDAQ:ARVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jeff Ball - Chief Financial Officer John Houston - Chief Executive Officer, President and
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Wednesday, 30'th Oct 2024
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $1.18 per share a year ago.
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Wednesday, 30'th Oct 2024
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
04:05pm, Tuesday, 22'nd Oct 2024
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas to Participate in Upcoming Investor Conferences
07:00am, Thursday, 29'th Aug 2024
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
09:20am, Tuesday, 30'th Jul 2024
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.25 per share a year ago.
